The Archive · 6 posts
Revolutionising medicine! 🚀 Oxford Biomedica (OXB) leads in gene and cell therapies, innovating treatments on the London Stock Exchange. 🧬
Oxford Biomedica reports 9% first-half revenue growth and record client wins, but delays and ordering changes weigh on 2026 guidance.
August 7, 2026
Showing 5 of 6 posts
Oxford Biomedica's 2025 results show 33% revenue growth, a swing to EBITDA profit, and a major new commercial supply deal with Bristol Myers Squibb.
JoshuaMarch 26, 2026
Oxford Biomedica acquires $4.5m FDA-approved viral vector plant in NC, expanding US commercial gene therapy capabilities.
JoshuaOctober 7, 2025
JoshuaSeptember 23, 2025
Oxford Biomedica reports explosive 38-44% H1 revenue growth (£70-73m) & £149m new orders, reaffirming FY2025 guidance. Surging demand fuels robust CDMO strategy.
JoshuaJuly 28, 2025
Oxford Biomedica's 2024 results: 44% revenue surge, H2 EBITDA profit, and £186m client orders as global CDMO expands.
JoshuaApril 9, 2025
September 23, 2025